Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open

Tectonic Therapeutic, Inc.

2024-Q2 EPS reported -$12.97

Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.
Cash and cash equivalents $185.1M as of June 30, providing runway into mid-2027.
TX45 Phase 2 APEX trial for PH-HFpEF open for screening; first dosing expected Sept 2024.
Closed reverse merger with AVROBIO in June 2024, with concurrent $130.7M private placement.
Appointed Dan Lochner as CFO in June 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.